Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)

• Intraocular pressure changes [ Time Frame: 28 days ] [ Designated as safety issue: No ]
• Visual Acuity [ Time Frame: 28 days ] [ Designated as safety issue: No ]

The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac following SLT.

Open label, single armed, cross over controlled study to evaluate comfort and IOP (Intraocular Pressure) changes of specific NSAIDs post SLT. Patients (n= 25, total 50 eyes) scheduled to undergo bilateral Selective Laser Trabeculoplasty (SLT) will instill bromfenac in the first eye to undergo SLT, and the contra lateral eye will receive nepafenac.

• Drug: Xibrom
  Xibrom: two times a day for seven days in the first eye.
  Other Name: bromfenac
• Drug: Nevanac
  Nevanac: three times a day for seven days in the second eye.
  Other Name: nepafenac

• Active Comparator: 1
  Xibrom (bromfenac)
  Intervention: Drug: Xibrom
• Active Comparator: 2
  Nevanac (nepafenac)
  Intervention: Drug: Nevanac

Inclusion Criteria:

• > 18 years old, either gender or any race.
• Diagnosis of open-angle glaucoma or ocular hypertension requiring laser trabeculoplasty.
• Completion of written and informed consent/authorization prior to any study related procedures.
• Able to follow study protocol and likely to complete study schedule.

Exclusion Criteria:

• Known sensitivity to NSAIDs.
• History of neovascular or ocular inflammatory disease.
• Current use of topical or systemic anti-inflammatory medications.
• Females of childbearing potential.